Table 1 of
Yousaf, Mol Vis 2011; 17:1153-1163. Table 1 of
Yousaf, Mol Vis 2011; 17:1153-1163.
Table 1. Genotype and allele frequency comparison of XRCC1 (c.1316G>A [rs25487]) in controls and patients and with gender distribution.
| Genotype | Male+Female Controls (n=193) | Male+Female POAG (n=160) | p (z) | p (χ2) | OR (95% CI) | Male+Female PCAG (n=163) | p (z) | p (χ2) | OR (95% CI) |
|---|---|---|---|---|---|---|---|---|---|
| GG | 98(51%) | 70(44%) | >0.05(1.32) | >0.05 (5.69) | DM=1.33(0.87–2.02) p>0.05 RM=0.65(0.35–1.21) p>0.05 | 79(48%) | >0.05(0.43) | >0.05(0.25) | DM=1.1(0.72–1.66) p>0.05 RM=1.13(0.64–1.97) p>0.05 |
| GA | 65(34%) | 73(46%) | <0.05(2.29) | 56(34%) | >0.05(0.13) | ||||
| AA | 30(15%) | 17(10%) | >0.05 (1.35) | 28(17%) | >0.05(0.42) | ||||
| Allele | Male+Female Controls | Male+Female POAG | p (χ2) | OR (95% CI) | Male+Female PCAG | p (χ2) | OR (95% CI) | ||
| G | 261(68%) | 213(67%) | >0.05(0.09) | 1.05(0.77–1.44) p>0.05 | 214(66%) | >0.05(0.31) | 1.09(0.8–1.49) | ||
| A | 125(32%) | 107(33%) | 112(34%) | p>0.05 | |||||
| Genotype | Male Controls (n=101) | Male POAG (n=80) | p (z) | p (χ2) | OR (95% CI) | Male PCAG (n=81) | p (z) | p (χ2) | OR (95% CI) |
| GG | 58(57%) | 27(34%) | <0.005(3.17) | 0.001(13.2) | DM=2.65(1.44–4.85) p<0.005 RM=0.82(0.35–1.91) p>0.05 | 38(47%) | >0.05(1.41) | >0.05(2.05) | DM=1.53(0.85–2.74) p>0.05 RM=1.2(0.55–2.62) p>0.05 |
| GA | 28(28%) | 43(54%) | <0.001(3.56) | 29(36%) | >0.05(1.17) | ||||
| AA | 15(15%) | 10(12%) | >0.05(0.46) | 14(17%) | >0.05(0.45) | ||||
| Allele | Male Controls | Male POAG | p (χ2) | OR (95% CI) | Male PCAG | p (χ2) | OR (95% CI) | ||
| G | 144(71%) | 97(61%) | <0.05(4.56) | 1.61(1.04–2.5) p<0.05 | 105(65%) | >0.05(1.33) | 1.3(0.83–2.03) p>0.05 | ||
| A | 58(29%) | 63(39%) | 55(35%) | ||||||
| Genotype | Female Controls (n=92) | Female POAG (n=80) | p (z) | p (χ2) | OR (95% CI) | Female PCAG (n=82) | p (z) | p (χ2) | OR (95% CI) |
| GG | 40(44%) | 43(54%) | >0.05(1.34) | >0.05(2.93) | DM=0.66(0.36–1.21) p>0.05 RM=0.49(0.2–1.25) p>0.05 | 41(50%) | >0.05(0.86) | >0.05(1.04) | DM=0.77(0.42–1.4) p>0.05 RM=1.06(0.48–2.32) p>0.05 |
| GA | 37(40%) | 30(37%) | >0.05(0.36) | 27(33%) | >0.05(1.0) | ||||
| AA | 15(16%) | 7(9%) | >0.05(1.48) | 14(17%) | >0.05(0.14) | ||||
| Allele | Female Controls | Female POAG | p (χ2) | OR (95% CI) | Female PCAG | p (χ2) | OR (95% CI) | ||
| G | 117(64%) | 116(72%) | >0.05(3.11) | 0.66(0.42–1.05) p>0.05 | 109(66%) | >0.05(0.32) | 0.88(0.57–1.37) p>0.05 | ||
| A | 67(36%) | 44(28%) | 55(34%) |